Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-CyBorD for Monoclonal Immunoglobulin Deposition Disease
NCT06418477Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in monoclonal immunoglobulin deposition disease (MIDD), sponsored by Peking University People's Hospital. Started Jun 2024; status: recruiting.
02
Drugs
daratumumab
03
Conditions
monoclonal immunoglobulin deposition disease (MIDD)
Beyond the preview
Go deeper on NCT06418477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418477.